Health, Medicine and Society Program

Speaker Biographies M to Z

Navid Madani, PhD
Navid Madani is an Iranian-American who left Iran during the Iran-Iraq war.  She obtained a PhD in biochemistry from Oregon Health Sciences University. In 2001, she became a pathology fellow at Harvard Medical School and since 2005 she has been an instructor in the department with a hospital appointment at Dana-Farber Cancer Institute. Currently her focus is small molecule HIV-1 entry inhibitors and microbicides. Dr. Madani regularly travels to the Middle East to facilitate interdisciplinary research and dialogue on emerging infectious diseases in the region. She serves as chair of the Grants Committee for Global Network of Researchers on HIV/AIDS in the Middle East and North Africa (GNR-MENA) and was co-chair of GNR-MENA’s session at the International AIDS conference in Toronto. She has given talks at the Middle East Association meetings in Washington, D.C. and Boston and hopes to use science education as a bridge for peace.

James Madara, MD
James L. Madara, MD, is the Chief Executive Officer of the University of Chicago Medical Center, the University Vice President for Medical Affairs, Dean of the Division of the Biological Sciences and the Pritzker School of Medicine, and Sara & Harold Lincoln Thompson Distinguished Service Professor at the University of Chicago. Dr. Madara, one of the nation's foremost academic pathologists, is a leading authority on epithelial cell biology and gastrointestinal disease for which he has been recognized with both national and international awards. He is the current President of the American Board of Pathology.

John Maeda, PhD, MBA
John Maeda is Associate Director of Research and E. Rudge & Nancy Allen Professor at the MIT Media Lab. He is a world-renowned graphic designer, visual artist, and computer scientist, and is a founding voice for “simplicity” in the digital age. Named by Esquire magazine as one of the 21 most important people for the twenty-first century, he first made his mark by redefining the use of electronic media as a tool for expression for people of all ages and skills. He is the recipient of the highest career honors for design in the United States, Japan, and Germany, and is the author of four books including his most recent work The Laws of Simplicity from MIT Press.

Rob Mashal, MD
Rob Mashal is Chief Executive Officer of Alinea, a pharmaceutical company dedicated to developing treatments for diabetes and related metabolic disorders. Before joining Alinea, Dr. Mashal was a partner at Boston Millenia Partners, a venture capital firm where he focused on investment opportunities in life sciences. He served as a director of EpiGenesis Pharmaceuticals, Novalar Pharmaceuticals, GlycoFi, Sapphire Therapeutics, CoApt Systems, Protein Forest, and Cardiomems. He also was a program executive with Vertex Pharmaceuticals, where he led cancer drug development strategy and oversaw pre-clinical and clinical development, marketing, regulatory, and business activities. He also was a member of the Joint Research Committee for the $800 million Vertex-Novartis collaboration. Prior to that, he was a consultant at McKinsey & Company, and a faculty member and attending physician at Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Harvard Medical School. Dr. Mashal received his MD from Johns Hopkins University School of Medicine.

Mark McClellan, MD, PhD
Mark McClellan is a Visiting Senior Fellow at the AEI-Brookings Joint Center for Regulatory Studies. Before his arrival at the Joint Center, Dr. McClellan served as Administrator for the Centers for Medicare and Medicaid Services and as Commissioner of the Food and Drug Administration (FDA). Prior to joining the FDA, he was Associate Professor of Economics and of Medicine, a practicing internist, and Director of the Program on Health Outcomes Research at Stanford University. He also formerly served in the White House as a member of the President's Council of Economic Advisers and as a senior policy director for health care. His research has included improving the quality of health care, estimating the effects of medical treatments, technological change in health care and its consequences, and the relationship between health and economic well-being. He received his MD from the Harvard-MIT Division of Health Sciences and Technology and his PhD in economics from MIT.

Michelle McMurry, MD, PhD
Michelle McMurry is Director of the Health, Biomedical Science, and Society Policy Program and the Aspen Health Forum at the Aspen Institute. She trained in pediatrics and molecular immunology. Since transitioning into health and science policy, her work has focused on the intersection of biomedical research funding policies and healthcare disparities and global health inequities. She has been a Global Health Fellow at the Council for Foreign Relations and is an Adjunct Assistant Professor of Health Policy at George Washington University. She was formerly a Robert Wood Johnson Health and Society Scholar at the University of California at Berkeley and San Francisco. She formerly oversaw health and social policy issues for Senator Joseph Lieberman and was the senior health policy advisor for the Lieberman for President Campaign. She also worked to improve diversity in graduate science education in the Office of the Director of the National Science Foundation as an AAAS Science Policy Fellow.

Peter McMurry, CFA
Peter McMurry was a software engineer for Microsoft, a co-founder of Red Storm Entertainment, and a financial analyst for Morgan Stanley before undergoing a successful double lung transplant at Columbia Presbyterian in October, 2006. He was diagnosed with Cystic Fibrosis at age four. He holds a bachelor's magna cum laude from Harvard College and a master's from the University of North Carolina at Chapel Hill, both in computer science.

Michael Milken, MBA
Michael Milken was called “The Man Who Changed Medicine” in a Fortune magazine cover story highlighting his three decades of work to accelerate medical research. In 1982, he formalized his previous philanthropy by co-founding the Milken Family Foundation, which has been a leader in support of worldwide research on various forms of cancer, pediatric neurological disorders and other diseases. He heads FasterCures, a Washington-based think tank dedicated to accelerating progress against all life-threatening diseases. He also chairs the Milken Institute, a major economic think tank. As a financier, he is often said to have revolutionized modern capital markets, making them more democratic by innovating a wide range of financing techniques previously unavailable to most companies. Starting in 1969, he financed thousands of companies that created millions of jobs. He is a graduate of the University of California at Berkeley and the University of Pennsylvania’s Wharton School. Details are at www.mikemilken.com.

Hala Moddelmog
Hala Moddelmog is President and Chief Executive Officer of Susan G. Komen for the Cure, which she joined in September 2006. As CEO, she is responsible for all aspects of the organization’s management and works closely with Komen for the Cure volunteers, staff and the board of directors. A five-year breast cancer survivor, she previously served as Founder and CEO of Catalytic Ventures, a private equity firm that consulted and invested in the food service industry. She was the first woman in corporate America to lead an international QSR brand (quick service restaurant) in 1995 when she was named president of Church's Chicken, a division of Atlanta-based AFC Enterprises. She subsequently led Church's to record sales and profit performance. She also held executive management and marketing positions at Church's Chicken, Arby's Franchise Association and BellSouth. Ms. Moddelmog holds a master's degree in journalism and mass communications from the University of Georgia.

R. Bartley Moore
Bart Moore is Executive Director of Research at Atlantic Media, a media company the holdings of which include The Atlantic and National Journal, its flagship publications. There he oversees diverse research projects covering the media industry, business development and strategy. Prior to Atlantic Media, he was Executive Director of the Advisory Board Company, the nation’s leading provider of health care industry best practice research and consulting. During 10 years as a senior researcher there, he led more than a dozen major research projects on topics including financial management, cost control and quality improvement. He has also served as the director of business development for Russia and Eastern Europe in the venture capital practice of a U.S.-based merchant bank and was assistant to the chairman and chief of the executive staff at Occidental Petroleum Corporation. He is a graduate of Georgetown University and of Oxford, where he was a Rhodes Scholar.

David Nabarro, CBE, FRCP
David Nabarro is the United Nations System Senior Coordinator for Avian and Human Influenza in the UN Development Group. Dr. Nabarro was appointed to his current post by Kofi Annan, UN Secretary General, in September 2005, and shortly thereafter was seconded to the position by the World Health Organization (WHO). Prior to joining the UN, Dr. Nabarro had served for six years at the WHO headquarters in Geneva. He started in 1999 as head of the Roll Back Malaria Program, then was promoted, in 2000, to be Executive Director in the Office of the then Director-General. In 2002 he led the WHO cluster on Sustainable Development and Healthy Environments. In 2003 he was made head of the newly-created Health Action in Crisis group, and special representative of Director General Dr. Lee Jong-Wook. Dr. Nabarro previously held leadership positions in the UK Department for International Development as well as the British Government's Overseas Development Administration.

Elizabeth Nabel, MD
Elizabeth G. Nabel is Director of the National Heart, Lung, and Blood Institute at the National Institutes of Health. Dr. Nabel leads an extensive international research portfolio with an annual budget of about $3 billion to prevent, diagnose, and treat heart, lung, and blood diseases. As a physician-scientist, Dr. Nabel has made substantial contributions to our understanding of the molecular genetics of cardiovascular diseases, which have led to the development of novel therapeutics and devices. She is the recipient of the Willem Einthoven Award, the Amgen-Scientific Achievement Award, and the American Heart Association Distinguished Achievement Award, as well as several honorary degrees. Dr. Nabel is an elected member of the Institute of Medicine, where she serves on its governing council.

Gary Nabel, MD, PhD
Gary J. Nabel is Director of the Vaccine Research Center in the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Dr. Nabel is well known as a molecular virologist and immunologist. His current research focuses on understanding viral gene expression and developing vaccines for HIV, Ebola virus, influenza and other emerging viruses. He completed the MD-PhD program at Harvard University followed by a postdoctoral fellowship with David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. Dr. Nabel’s achievements include appointment to the Institute of Medicine of the National Academy of Sciences and the Association of American Physicians. He has served as a councilor for the American Academy for the Advancement of Science and as a scientific reviewer or adviser for organizations including the Keystone Symposia, the AIDS Clinical Trial and Vaccine Trials Networks, and the Gates Foundation.

Norman Neureiter, PhD
Norman P. Neureiter is Director of the Center for Science, Technology and Security Policy at the American Association for the Advancement of Science, a post he has held since 2003. Prior to that, Dr. Neureiter was appointed as a Distinguished Presidential Fellow for International Affairs at the National Academy of Sciences, which followed his completion of a three-year assignment as the first Science and Technology Adviser to the U.S. Secretary of State. In 1973, Dr. Neureiter joined Texas Instruments (TI), where he held several positions, including Manager, East-West Business Development; Manager, TI Europe Division; Vice President, Corporate Staff; and Vice President of TI Asia, where he was resident in Tokyo for five years. He obtained his PhD in organic chemistry from Northwestern University and was a Fulbright Fellow in the Institute of Organic Chemistry at the University of Munich. He speaks German, Russian, Polish, French, Spanish and Japanese.

Eve Nichols
Eve Nichols is Vice President, Science, at the Fidelity Foundations in Boston. Prior to her arrival at Fidelity in September 2001, she was Director of Institutional Advancement at the Whitehead Institute for Biomedical Research. Working with Whitehead faculty, Ms. Nichols launched science education programs for high school teachers, established a nationally acclaimed task force on genetics and public policy, and developed grant proposals to fund major initiatives in structural biology, imaging, cancer research, and other fields. Before arriving at Whitehead in 1991, Ms. Nichols was a freelance writer and editor whose clients included the Institute of Medicine, the World Health Organization, and the American Association for the Advancement of Science. She is the author of three books, including Human Gene Therapy (Harvard University Press, 1988), which won first place in the American Medical Writers Association Medical Book Award Competition. Ms. Nichols graduated Phi Beta Kappa from Stanford University in 1974.

Trent W. Nichols, MD
Trent Nichols is a board certified internist, nutritionist and gastroenterologist who is a fellow of the American College of Nutrition, certified nutritional specialist, and member of the Pennsylvania Society of Gastroenterology, Society for Neuroscience, International Tissue Engineering and Regenerative Medicine Society, and Bioelectromagnetic Society. He additionally is an active physician scientist involved in pharmaceutical, nutritional and bioelectromagnetic medical research. He received his bachelor's in chemistry from the University of Denver and his MD from Northwestern University Medical School. His residency in internal medicine and gastroenterology fellowship also were completed at Northwestern University. After 28 years of private practice at the Center for Nutrition and Digestive Disorders, Dr. Nichols is a gastroenterologist at Veterans Administration Hospital of Lebanon, Pennsylvannia. He is the author of Optimal Digestive Health. A Complete Guide (Healing Arts Press, 2005) and blogs for RevolutionHealth.com. In addition, Dr. Nichols was named to America's Top Physicians 2003-2005 by Consumers’ Research Council of America.

John Niederhuber, MD
John E. Niederhuber is Director of the National Cancer Institute (NCI). A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his career to the treatment and study of cancer — as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator. In addition, under his leadership, the Laboratory of Tumor and Stem Cell Biology is studying tissue stem cells as the cell-of-origin for cancer and is studying the complex relationship between tumor cells and their microenvironment. Dr. Niederhuber also holds a clinical appointment on the NIH Clinical Center medical staff. As a surgeon, his emphasis is on gastrointestinal cancer, hepatobiliary (liver, bile duct, and gallbladder) cancer, and breast cancer.  He is recognized for his pioneering work in hepatic artery infusion chemotherapy and was the first to demonstrate the feasibility of totally implantable vascular access devices.

Larry Norton, MD
Larry Norton is Deputy Physician-in-Chief for Breast Cancer Programs and Norna S. Sarofim Chair in Clinical Oncology at Memorial Sloan-Kettering Cancer Center. In addition, Dr. Norton is Chair of the Breast Committee of the National Cancer Institute's Cancer and Leukemia Group B and a Presidential Appointee to the National Cancer Advisory Board of the NCI. Dr. Norton, a breast oncologist, is renowned as a leader in the development of drug treatments for breast cancer. His work has established the value of using sequential combinations of drugs to overcome different drug sensitivities among tumor cells. He is known in particular for his experimental and theoretical studies of the proliferation rates of tumor cells. Dr. Norton has been honored by many organizations, including the Don Shula Foundation, Cancer Care, and the Susan G. Komen Foundation. He received his MD from the Columbia University College of Physicians and Surgeons.

Gilbert Omenn, MD, PhD
Gilbert S. Omenn is Professor of Medicine, Genetics, Public Health and Computational Biology at the University of Michigan, where he also serves as Director of the Center for Computational Medicine & Biology and the Proteomics Alliance for Cancer Research. From 1997 to 2002, Dr. Omenn was CEO and Executive Vice President for Medical Affairs of the University of Michigan Health System. His research interests include cancer proteomics, chemoprevention of cancers, public health genetics, science-based risk analysis, and health policy. Among his achievements, Dr. Omenn served as Associate Director, Office of Science and Technology Policy, and Associate Director, Office of Management and Budget, in the Executive Office of the President in the Carter Administration. He also was President of the American Association for the Advancement of Science in 2006. He received his MD magna cum laude from Harvard Medical School and his PhD in genetics from the University of Washington.

Dean Ornish, MD
Dean Ornish is Founder, President and Director of the non-profit Preventive Medicine Research Institute in Sausalito, California, and Clinical Professor of Medicine at the University of California, San Francisco. For the past 25 years, Dr. Ornish has directed clinical research demonstrating that comprehensive lifestyle changes may begin to reverse even severe coronary heart disease, without drugs or surgery. He is the author of five best-selling books, including New York Times' bestsellers Dr. Dean Ornish's Program for Reversing Heart Disease, Eat More, Weigh Less, and Love & Survival. Dr. Ornish is a member of the board of directors of the U.S. United Nations High Commission on Refugees, the Quincy Jones Listen Up Foundation, and the Wheelchair Foundation. Additionally, he has served on The White House Commission on Complementary and Alternative Medicine Policy. Dr. Ornish received his medical training from the Baylor College of Medicine, Harvard Medical School and Massachusetts General Hospital.

Peter Orszag, PhD
Peter Orszag is Director of the Congressional Budget Office. Before joining the federal office, Dr. Orszag was the Joseph A. Pechman Senior Fellow and Deputy Director of Economic Studies at the Brookings Institution. In previous government service, he was Special Assistant to the President for Economic Policy and Senior Economic Adviser at the National Economic Council. Dr. Orszag has coauthored a number of books, including Aging Gracefully: Ideas to Improve Retirement Security in America (2006) and Saving Social Security: A Balanced Approach (2004). His main areas of research have been pensions, Social Security, budget policy, higher education policy, homeland security, macroeconomics, and tax policy—topics on which he has published widely in academic journals. Dr. Orszag graduated summa cum laude in economics from Princeton University and received his master’s and PhD in economics from the London School of Economics, which he attended as a Marshall scholar.

Jessica Owens, MBA
Jessica Owens is a Partner at Kleiner Perkins Caufield & Byers, having joined the firm in 2006 to work on investments in pandemic preparedness and bio-defense. She brings experience in global public health and infectious disease research from four years at the Centers for Disease Control and Prevention, where she was a scientist in the Special Pathogens Branch. Her work resulted in the discovery and demonstration of genetic shift among Hantavirus strains. She also worked on the development of PCR-based diagnostic assays and conducted Hantavirus field surveillance. Prior to KPCB, she worked in equity research covering the diagnostics industry at Thomas Weisel Partners. She also worked in corporate finance as part of the life sciences investment banking team at Robertson Stephens. In addition, she worked in Oncology R&D Project Finance at Genentech. She received an MBA from Harvard Business School, a master’s from the Department of Cancer Biology at Stanford University, and a bachelor’s in biology from Agnes Scott College.

Jessica Owens, MS, MBA
Jessica Owens is a Partner at Kleiner Perkins Caufield & Byers focusing on life sciences investments. At KPCB, she has been a founding partner in four start-up ventures in the areas of diagnostics, antivirals, oncology, and personalized medicine. She brings experience in global public health and virology from her work at the CDC where she was a scientist in the Special Pathogens Branch. She also conducted research at Stanford University on cell cycle checkpoint proteins in the Department of Cancer Biology. Prior to KPCB, she worked in Oncology R&D Project Finance at Genentech. She also spent three years on Wall Street in equity research at Thomas Weisel Partners covering the diagnostics industry and in corporate finance at Robertson Stephens. She received an MBA from Harvard Business School, a master's from the Department of Cancer Biology at Stanford University, and a bachelor's in biology from Agnes Scott College.

 

John Parr, JD
John Parr is Co-Founder of Civic Results, a non-profit organization based in Denver that assists governments, businesses and non-profit institutions in planning and implementing initiatives that create measurable change in the physical, social, civic and human infrastructure of communities and regions. He is currently directing the implementation of the Metro Denver Health and Wellness Commission. He also serves as Senior Counsel of the Alliance for Regional Stewardship, for which he was the founding President and CEO, a national network of practitioners that is using metropolitan or rural regional approaches for community problem solving. Mr. Parr is an associate of the Citistates Group working on issues of regional governance in the United States. He is also on the Board of the Children and Nature Network. Mr. Parr is an attorney with extensive experience in public administration, strategic planning, mediation, public interest group management and political campaign organization. He received his law degree from the University of Denver.

Aaron Peirsol
Aaron Peirsol is a competitive swimmer and a two-time Olympian.  At the 2004 Olympic Games in Athens, Greece, Aaron won gold medals in the 100m Backstroke, 200m Backstroke and 4x100 Medley Relay, sweeping all of the backstroke events, and becoming the fifth male swimmer and fourth American to do so.  At the 2000 Olympic Games in Sydney, Australia, he earned a silver medal in the 200m Backstroke.  In 2007, Aaron broke his own 100m Backstroke record at the World Championships and became the first man to finish in less than 53 seconds.  He is also a decorated medalist at multiple World Championships, and is currently training for the 2008 Games in Beijing.  In his spare time, Aaron is earning his degree in government from the University of Texas and is the spokesperson for Oceana, a clean-ocean advocacy group that he supports through Aaron Peirsol’s Race for the Oceans.

Georg-Andreas Pogany
Georg-Andreas Pogany is a retired Sergeant First Class (SFC) and Operation Iraqi Freedom Veteran. After obtaining a bachelor’s in criminology from the University of South Florida, he enlisted in the U.S. Naval Reserve. In 1998, he switched services and enlisted in the Army, where he trained as a nuclear, biological and chemical warfare specialist. In 2003, he was deployed to Iraq as part of a Special Forces unit. There, he became incapacitated by toxic drug levels from the anti-malarial drug Lariam/Mefloquine. He was sent to Fort Carson, Colo., where he was diagnosed with a related brain injury. He received treatment and shortly thereafter was honorably discharged. Since his retirement from the Army, he has worked as a veteran’s and active duty service member advocate on health care, combat stress, and military justice. He created and manages “J1W2,” Just One Wounded Warrior, which connects veterans and active duty service members with mental health care professionals.

John Porter, JD
John Porter, a partner at the firm Hogan & Hartson, concentrates his practice on health law and education. Mr. Porter previously served 21 years as a U.S. congressman from the 10th district in Illinois, where he served on the Appropriations Committee and was Chair of the Subcommittee on Labor, Health and Human Services, and Education. Before his election to Congress, Mr. Porter served in the Illinois House of Representatives and prior to that as an honor law graduate attorney with the U.S. Department of Justice in the Kennedy Administration. He founded and Co-chaired for 18 years the Congressional Human Rights Caucus, which has included more than 250 congressmen working to end human rights violations worldwide. Among his accomplishments, Mr. Porter received the Mary Wood Lasker Award for Public Service for leadership on behalf of medical research. He studied at MIT and obtained his undergraduate degree from Northwestern University, and his law degree from the University of Michigan.

Amy McGuire Porter
Amy McGuire Porter is Executive Director of the Foundation for the National Institutes of Health, a position she has held since 2001. Prior to that she was its director of development. Under Ms. Porter’s leadership, the foundation’s portfolio of programs has grown to some 50 programs currently under its management and supported by about $400 million generated from private contributions. The foundation is a global leader in the creation of specially configured, high-impact, public-private partnerships in biomedical research. Prior to joining the foundation, Ms. Porter served as director of development of the National AIDS Fund, an organization dedicated to reducing the impact of HIV/AIDS in America’s communities. Previously, she also was national director of development for Volunteers of America, a national nonprofit organization that provides health and human service programs to 1.5 million people across the United States each year. Ms. Porter is a graduate of Kent State University.

Franklyn Prendergast, MD, PhD
Franklyn G. Prendergast is Edmond and Marion Guggenheim Professor of Molecular Pharmacology and Experimental Therapeutics and Director of the Center for Individualized Medicine at the Mayo Clinic College of Medicine. Dr. Prendergast also serves on the Board of Trustees of the Mayo Foundation and the Board of Directors of Eli Lilly and Company. His research focuses on structural protein biology and bioimaging and has earned him numerous accolades, including an E.E. Just Award from the American Society of Experimental Biology and the Musgrave Gold Medal of the Institute of Jamaica. In a prior position at the Mayo Clinic, Dr. Prendergast served as Director of the Mayo Clinic Comprehensive Cancer Center. He earned his BA and MA in physiology as a Rhodes Scholar at Oxford University, his PhD in biochemistry from the University of Minnesota and his MD from the University of the West Indies.

Franklin Raines, JD
Franklin D. Raines is a Founder and Vice Chairman of the Board of Revolution Health Group LLC, which creates products and services for consumers in the growing market of consumer-directed health care. He is the retired Chairman and CEO of Fannie Mae, the largest non-bank financial services company in the world. In his six years as Chairman and CEO, Fannie Mae provided more than $3.4 trillion of housing financing serving more than 30 million families. Prior to joining Fannie Mae in 1991, Mr. Raines was a General Partner of the investment banking firm of Lazard Freres & Co., where he provided financial advice to public and private clients. Among his many other leadership positions, he served in the Cabinet of President Bill Clinton as Director of the Office of Management and Budget, and in the Administration of President Jimmy Carter as Assistant Director of the White House Domestic Council and Associate Director of the Office of Management and Budget.

N. Krishna Reddy
N. Krishna Reddy is co-founder of Care group, consisting of Care Hospitals (delivery systems); Care Foundation (education & training, research & development, and societal initiatives); and Care Polymed (Cost-effective medical product development and production). He has been a core member of the Care Team working towards evolving global high-quality, cost-effective healthcare delivery solutions. Dr. Reddy was involved in the development and evaluation of cost-effective coronary stents and catheter-based products. He has 20 national and international scientific publications to his credit. Dr. Reddy is currently principal investigator for five ongoing national and international trials, and is the team leader for the ongoing development of drug-eluting stents. Dr. Reddy graduated from Osmania Medical College, Hyderabad, India, with honors. He completed his post-graduate work in internal medicine and his fellowship in cardiology. He joined Nizam’s Institute of Medical Sciences in Hyderabad as Assistant Professor of Cardiology, and later worked at Mediciti Hospitals.

Tannishtha Reya, PhD
Tannishtha Reya is Assistant Professor of Pharmacology and Cancer Biology and Co-director of the Stem Cell Research Program at the Duke University School of Medicine. Dr. Reya obtained her bachelor’s degree from Williams College and her PhD from the University of Pennsylvania. She subsequently completed her postdoctoral training at the University of California at San Francisco and Stanford University. Her work has provided insight into the signals that control stem cell growth, and how the same signals are subverted to fuel cancer growth. Her awards include the Cancer Research Institute Scholar award, the Leukemia and Lymphoma Society Scholar award, as well as the Presidential Early Career Award for Scientists and Engineers.

Richard Robb, PhD
Richard A. Robb is Scheller Professor in Medical Research, Professor of Biophysics and Professor of Computer Science at the Mayo Clinic College of Medicine, where he also serves as Director of the Mayo Biomedical Imaging Resource. Widely regarded as a pioneer of biomedical imaging, Dr. Robb is a founding member and Executive Director of the Medical Image Computing and Computer Assisted Intervention Society. He has written more than 400 publications in the field, including 5 books and 30 book chapters. He also has patented several inventions related to medical imagery and its application to clinical procedures. Dr. Robb's current research interests are in image-guided interventions, multi-dimensional image fusion and design of new-generation paradigms for biomedical imaging and visualization systems, particularly for medical treatment planning, minimally invasive clinical procedures, and medical training and education. He holds graduate degrees in computer science and biophysics from the University of Utah.

Jimmy Roberts
Jimmy Roberts serves as NBC Sports’ interviewer and essayist on its golf and tennis coverage. He has also handled reporting assignments for the 2000 Sydney Olympic Games; the 2000 American League Division Series and ALCS; the Presidents Cup, and the Breeders’ Cup. He has received critical acclaim for his Olympic segments and he won an Emmy Award for his “Olympic Moments” features during NBC’s coverage of the Sydney and Salt Lake Olympics. Prior to joining NBC Sports in 2000, Roberts had a long and much-honored career at ABC and ESPN. While at ESPN, he served as a SportsCenter correspondent and covered the World Series, the NBA Finals, the Super Bowl and the 1992 and 1994 Winter Olympics. He earned his bachelor's in radio/television and film from the University of Maryland in 1979, and over the course of his career has won 13 Sports Emmy Awards.

Mary Robinson, LLB, LLM
Mary Robinson is President of Realizing Rights: The Ethical Globalization Initiative, in partnership with the Aspen Institute, Columbia University and the International Council for Human Rights Policy. Mrs. Robinson served as United Nations High Commissioner for Human Rights from 1997 to 2002 and as President of Ireland from 1990 to 1997. Before her election as President, she served as Senator, holding that office for 20 years. Educated at Trinity College in Ireland, Mrs. Robinson holds law degrees from the King's Inns in Dublin and from Harvard University. She is Chair of the Council of Women World Leaders, Vice President of the Club of Madrid, honorary President of Oxfam International, a board member of the GAVI Fund Board and Chair of the GAVI Fund Executive Committee, and a member of the Leadership Council of the UN Global Coalition on Women and AIDS. She also co-chairs the Health Worker Global Policy Advisory Council.

Barbara Romberg, PhD
Barbara V. Romberg, Founder and Executive Director of Give an Hour, is a licensed clinical psychologist who has been practicing in the Washington, D.C., area for 16 years. She specializes in the diagnosis and treatment of children. Dr. Romberg has spent her career interacting with and coordinating services within large systems, including school districts and mental health clinics. In addition, for many years, she served as an adjunct faculty member at George Washington University, where she trained and supervised developing clinicians. She received her PhD in clinical psychology from the University of Maryland in 1991. Concerned about the mental health implications of the Iraq War, Dr. Romberg founded Give an Hour in 2005. Give an Hour is a nonprofit organization that is creating a national network of mental health professionals who are providing free services to U.S. troops, veterans and their families.

Eric Rose, MD
Eric Rose is Executive Vice President for Life Sciences at MacAndrews & Forbes and CEO of Siga Technologies, Inc., a developer of anti-viral drugs directed at potential agents of bioterror. He is on leave from his position as Surgeon in Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons, where he holds a distinguished professorship. An accomplished heart surgeon, researcher and entrepreneur, Dr. Rose has grown one of the nation's premier departments of surgery over the past 25 years while managing, investigating and developing complex medical technologies such as for heart transplantation and novel approaches to Alzheimer’s disease and bioterrorism. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984, and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He received his MD from Columbia University.

Steven Rosenberg, MD, PhD
Steven A. Rosenberg is Chief of Surgery at the National Cancer Institute and Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. He also has pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans and to conduct clinical studies of the gene therapy of cancer. He received his MD at the Johns Hopkins University School of Medicine, and his PhD in biophysics at Harvard University. After completing his residency in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, he became the NCI Chief of Surgery. In addition to that position, which he continues to hold, he is Head of the NCI Tumor Immunology Section.

Wayne Rosenkrans, Jr., PhD
Wayne A. Rosenkrans, Jr. is Scientific and Medical Strategy Director for External Medical Relations at AstraZeneca Pharmaceuticals. He is responsible for long-range strategy development supporting AstraZeneca’s external scientific alliances and policy. He also is Chairman and President and a member of the board of directors of the Personalized Medicine Coalition, a Washington, D.C., based organization working with government and other agencies on evolving health policy for personalized health care. Previous positions include Global Director, Intelligence Affairs at AstraZeneca, and Associate Director and Head of Strategic Intelligence for SmithKline Beecham Pharmaceuticals R&D. He is a recipient of the Society of Competitive Intelligence Professionals Fellows Award, and one of its former presidents. Dr. Rosenkrans holds a bachelor’s in biology from MIT and a PhD in cell and molecular biology from Boston University. He received postdoctoral training in cancer and radiation biology at the University of Rochester.

Leonard Rubenstein, JD
Leonard Rubenstein is President of Physicians for Human Rights, an organization that mobilizes the health professions to advance human rights. He has been a leader in promoting health policy on the basis of human rights both in the United States and in the developing world. He initiated the Health Action AIDS Campaign, which brings the knowledge and voices of physicians and other health professionals, both in the United States, and in Africa, to advocacy for resources and sound policy on HIV/AIDS. He also has been at the forefront of a broad effort to increase human resources for health in Africa. Mr. Rubenstein has conducted human rights investigations throughout the world and has published widely, from academic journals to the op-ed pages of The Washington Post and The New York Times. He has received numerous awards, including the Health Care Hero Award from the Congressional Minority Caucuses.

Ellis Rubinstein
Ellis Rubinstein is President and CEO of the New York Academy of Sciences. Prior to this position, Mr. Rubinstein served as Editor of Science magazine with the American Association for the Advancement of Science. He also served as Editor of The Scientist and as a senior editor at Newsweek. During his three decades in journalism, he was thrice honored by the National Magazine Awards – the Pulitzer Prizes of the periodical industry. He conducted the first one-on-one interview with Chinese President Jiang Zemin granted to a Western magazine and garnered President Bill Clinton's first interview with a science publication. Additionally, he wrote the most complete investigative report of the Three Mile Island nuclear power accident and a much cited investigative report on the true derivation of the cell line in which the AIDS virus was first grown. A graduate of UC Berkeley, Mr. Rubinstein taught high school English before entering publishing.

David Scadden, MD
David T. Scadden is Professor of Medicine at Harvard Medical School and Director of the Massachusetts General Hospital Center for Regenerative Medicine and Technology. He also is Co-Director of the Harvard Stem Cell Institute. Dr. Scadden’s research focuses on reconstituting immune function using the stem cells that form blood cells to fight cancer and AIDS, and he is widely recognized as one of the nation's leading experts in the treatment of HIV-related Kaposi's sarcoma and B-cell lymphoma and has developed a number of new therapies for them. Dr. Scadden received his training at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He has received numerous honors and awards, including the Alpha Omega Alpha; Edwin C. Garvin, MD Senior Prize; Doris Duke Innovation in Clinical Research Award; the Burroughs Welcome Fund Clinical Scientist Award in Translational Research; and the Brain Tumor Society's Alan Goldfine Leadership Chair of Research.

Andrew Schiff, MD, MBA
Andrew Schiff is a Managing Director of Aisling Capital II, llc. and the Perseus-Soros biopharmaceutical fund. He joined the fund in September of 1999. Prior to his arrival at Perseus-Soros, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital, where he maintains his position as a clinical assistant professor of medicine. He currently serves on the board of directors of Armgo pharmaceuticals, Cardiokine, Dynova, Skinmedica, Cempra, and Sirion. Dr. Schiff received his MD from Cornell University Medical College and his MBA from Columbia University. His bachelor's degree in neuroscience was awarded with honors by Brown University.

Eric Schlosser
Eric Schlosser, an award-winning journalist, is a correspondent for The Atlantic Monthly. His work has also appeared in Rolling Stone, Vanity Fair, The Nation, and The New Yorker, among other publications. He may be best known for his 2001 book, Fast Food Nation: the Dark Side of the All-American Meal, which is assigned reading at universities across the country. The book, begun as a Rolling Stone article, is a groundbreaking work that changed the way America thinks about the way it eats. Mr. Schlosser exposed the role the fast-food industry has played in American society, from the development of urban and rural landscapes, to the changes in the meat packing industry and in workplace conditions for employees, to the impact abroad. Among his accomplishments, Mr. Schlosser has received a National Magazine Award and a Sidney Hillman Foundation Award for reporting. All three of his books have been national bestsellers.

Mark Siegler, MD
Mark Siegler is Director of the MacLean Center for Clinical Medical Ethics and Lindy Bergman Distinguished Service Professor of Medicine and Surgery at the University of Chicago. A general internist, Dr. Siegler focuses on clinical medical ethics, including the doctor-patient relationship, informed consent, end-of-life care, and issues related to organ transplantation. He has been the recipient of more than 25 federal and foundation research grants, and has published more than 150 journal articles, 50 book chapters, five books, and other publications. His latest book, co-authored with Drs. Albert Jonsen and William Winslade, Clinical Ethics: A Practical Approach to Ethical Decisions in Clinical Medicine, 5th Edition (2002), is widely used by health professionals throughout the country. After receiving his bachelor’s degree from Princeton University, Dr. Siegler attended medical school and completed his internship and residency at the University of Chicago, and then did advanced training at the Hammersmith-Royal Postgraduate Hospital in London.

Greg Simon, JD
Greg Simon is President of FasterCures/The Center for Accelerating Medical Solutions, a nonprofit, nonpartisan organization that examines the medical research and development process to discover and promote ways to speed the discovery, development and deployment of new medical treatment for today’s deadly diseases. Prior to joining FasterCures in 2003, Mr. Simon was a principal at Infotech Strategies, a Washington, D.C. consulting firm with expertise in health technology, biotech, education technology and communication technology. Earlier, he was CEO of Simon Strategies/Mindbeam, a consulting firm specializing in biotechnology, healthcare, technology and information technology, among other issues. From 1993 to 1997, Mr. Simon was Chief Domestic Policy Advisor to Vice President Al Gore, specifically with regard to economic, science, and technology issues, and he played a leading role in a variety of related White House policies and programs. He received his law degree from the University of Washington School of Law.

Stewart Simonson, JD
Stewart Simonson is Vice President for Global Public Health Preparedness at the Constella Group, charged with oversight and strategic expansion of the company’s preparedness programs. Prior to joining Constella, Dr. Simonson served as Assistant Secretary for Public Health Emergency Preparedness at the U.S. Department of Health and Human Services (HHS), where he was the secretary’s principal adviser on bioterrorism and other public health emergency matters. While at HHS, he also coordinated the public health preparedness activities of the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health. In addition, he represented HHS in negotiations with foreign governments and international agencies, and was instrumental in preparedness planning for Pandemic Avian Influenza. Dr. Simonson has received several awards, including The Surgeon General’s Medallion and the FDA Center for Biologics Evaluation and Research Public Health Achievement Award. He holds a JD from the University of Wisconsin.

Sri Sivakumar
Sri Sivakumar is the Chief Executive of ITC’s Agri-Business Division. ITC Limited (www.itcportal.com) is one of India’s foremost private sector companies with a market capitalization of nearly $15 billion and sales of more than $5 billion. The company is known for its thought and action leadership. Mr. Sivakumar leads ITC’s famous eChoupal initiative, which facilitates two-way flow of goods and services into and out of villages. Servicing the production and consumption needs of some four million families in 38,000 villages, ITC’s eChoupal is the largest Internet-based intervention in rural India. The initiative has won numerous awards, including the United Nations Development Program World Business Award, Stockholm Challenge Award and Development Gateway Award. Bringing high quality health services to rural India at affordable cost, in partnership with service providers such as Apollo Hospitals and Care Foundation, is ITC eChoupal’s latest foray.

Jay Skyler, MD, MACP
Jay Skyler is Professor of Medicine, Pediatrics & Psychology in the Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, University of Miami Miller School of Medicine. He served as Director of that Division from 2000 to 2004. At the University of Miami, he is Associate Director for Academic Programs in the Diabetes Research Institute. He also is Chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, an international network conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. Dr. Skyler’s research interests are in clinical aspects of diabetes, particularly improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention. He is widely acclaimed for developing “algorithms” for patient adjustment of insulin doses. He is a past president of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice-President of the International Diabetes Federation.

Stuart Smith, JD, MBA
Stuart F. Smith is a Managing Director of Credit Suisse and Head of Health Care within the Investment Banking Department, based in New York. Prior to joining Credit Suisse First Boston in 1999, Mr. Smith was a Managing Director of Alex Brown & Sons and its successor firms. He has been involved in structuring numerous mergers and acquisitions as well as effecting financings for clients across all sectors of the health care industry. Mr. Smith received an MBA from the Columbia Business School, a law degree from the University of Connecticut School of Law and a bachelor's from Franklin and Marshall College.

Steven Southwick, MD
Steven Southwick is Professor of Psychiatry at Yale Medical School and the Yale Child Study Center, Adjunct Professor of Psychiatry at the Mt. Sinai School of Medicine and Deputy Director of the Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder. He is an expert on the psychological and neurobiological effects of extreme psychological trauma. Dr. Southwick has served on the Board of Directors of the International Society for Traumatic Stress Studies and on the editorial board of the Journal of Traumatic Stress. He has published extensively on the phenomenology and neurobiology of PTSD, the longitudinal course of trauma-related psychological symptoms, memory for traumatic events, treatment of PTSD and on neurobiological and psychological factors associated with resilience to stress. He has worked with a wide range of stress sensitive and stress resilient individuals including combat veterans with PTSD, civilian children and adults with PTSD and very high functioning stress-resilient prisoners of war and active Special Forces soldiers.

Bruce Stillman, PhD
Bruce Stillman is President and Chief Executive Officer of Cold Spring Harbor Laboratory. A native of Australia, Dr. Stillman joined the laboratory as a postdoctoral fellow in 1979 and has remained there ever since, advancing among the ranks. He was appointed Director of the laboratory’s Cancer Center in 1992, and two years later succeeded Nobel laureate James Watson as Director of the institution. Dr. Stillman was named President and CEO in 2003. His research focuses on how DNA replication is duplicated in cells, a process that ensures accurate inheritance of genetic material from one generation to the next. He has helped shed light on the mechanism of DNA replication of human viruses and the processes that ensure accurate replication of the human genome and its associated protein structures. His honors include election as a Fellow of The Royal Society and as foreign associate of the U.S. National Academy of Sciences as well as receipt of the 2004 Alfred P. Sloan prize.

Edwin Stone, MD, PhD
Edwin M. Stone is Director of the Carver Family Center for Macular Degeneration and the Carver Nonprofit Genetic Testing Laboratory at the University of Iowa. Dr. Stone is well known for his work in defining the genetic basis of blinding eye disease, including the two most common causes of blindness: macular degeneration and glaucoma. He also has been active in removing the technical, legal and financial barriers between genetic discoveries and patients who could benefit from them. Dr. Stone founded a nonprofit genetic testing laboratory at the University of Iowa that provides low cost tests for more than 20 different inherited eye diseases. He received his MD and PhD from the Baylor College of Medicine and his training in vitreoretinal surgery at the University of Iowa, where he joined the faculty in 1990. He holds the university’s Seamans-Hauser Chair of Molecular Ophthalmology and is a Howard Hughes Medical Institute Investigator.

Picabo Street
Picabo Street is a three-time Olympian in alpine skiing who competed in the 1994, 1998 and 2002 Winter Games, and a two-time Olympic medalist. Picabo captured the gold medal in the Super G at the 1998 Olympic Games in Nagano, Japan and the silver medal in Downhill in the 1994 Olympic Games in Lillehammer, Norway. She was a decorated medalist at multiple World Championships, World Cups and U.S. National Championships, capturing medals in the Downhill, Super G, Combined Downhill and Combined Events. During the 1995-1996 and the 1996-1997 seasons, she won the World Cup Overall Title in Downhill. Picabo was named the U.S. Olympic Committee Sportswoman of the Year in 1995 and 1998, and in January 2005, she was inducted into the U.S. National Ski Hall of Fame. Since retiring from competitive skiing in 2002, Picabo has completed broadcasting assignments with NBC’s Today Show, CBS Sports, NBC Sports, OLN, FineLiving Network and RSN.

Jack Taunton, MD
Jack Taunton is the Chief Medical Officer for Vancouver 2010 Olympic and Paralympic Winter Games.  He previously served as the Chief Medical Officer for Canada at the Sydney Olympics, two Pan American and two World Student Games, and he has more than 25 years of experience providing medical support for Canadian national and professional sports teams and athletes.  Dr. Taunton continues to have a clinical practice in sports medicine at the Allan McGavin Sports Medicine Centre, which he co-founded, and he is a Professor in the Faculty of Medicine and School of Human Kinetics at the University of British Columbia.  Dr. Taunton is a past president of the Canadian Academy of Sport Medicine and SportMed BC, which he co-founded.  In 2000, he was honored as the Canadian Sport Physician of the Year.

Elizabeth Teisberg, PhD
Elizabeth Teisberg is Co-Author of Redefining Health Care, which is refocusing the health care dialogue on the issue of driving improvement in value for patients. By focusing on the central issue of improving care delivery, the book moves the discussion from cost containment and cost shifting to the fundamental and critical issues of health and care. For this work, Dr. Teisberg has received The Wachovia Award for Research Excellence, and Professors Porter and Teisberg received The Book of the Year Award from the American Academy of Health Care Executives. Dr Teisberg is Associate Professor of Business Administration at the University of Virginia Darden Graduate School of Business. For more information on Dr. Teisberg and her work, please visit http://www.hbs.edu/rhc/.

Brian Thiele, MD
Brian Thiele is Professor of Surgery at the University of Queensland, Australia. He has spent most of his professional life in the United States, where he was initially a faculty member in the Department of Surgery at the University of Washington. During this tenure, he was a principle investigator in the early basic research and development of the use of ultrasound, particularly in the area of the diagnosis of vascular disease. Dr. Thiele was subsequently appointed Professor and Vice Chairman of the Department of Surgery at Pennsylvania State College of Medicine, where he continued his basic and clinical research in this field. During this time, he developed an international reputation as an expert in the field of diagnostic ultrasound. He has published widely in scientific peer review journals and written numerous book chapters. Professor Thiele is a graduate of the University of Queensland, Australia.

Hon. Tommy G. Thompson, JD
Tommy Thompson is a Senior Partner at Akin Gump Strauss Hauer & Feld LLP, a Washington, D.C., law firm, and is former Secretary of the U.S. Department of Health and Human Services. In his position as Secretary, he served as the nation's leading advocate for the health and welfare of all Americans. He worked to modernize and add prescription drug coverage to Medicare for the first time in the program's history. A leading proponent of welfare reform, Secretary Thompson also focused on expanding services to seniors, the disabled and low-income Americans. Additionally, he was Chairman of the Global Fund to Fight AIDS, Tuberculosis and Malaria, and as such helped elicit unprecedented investment to stop the spread of these diseases worldwide. Prior to these positions, Secretary Thompson served as the Governor of Wisconsin, working to expand health care access across all segments of society. He earned his law degree from the University of Wisconsin, Madison.

Priyadarshi Tiwari, MD
Priyadarshi Tiwari is heading the Department of Community Health and Wellness Services at Care Hospitals, Hyderanad, India. Dr. Tiwari is an internist with a keen interest in designing healthcare service delivery modules for improving the health status of the community, and his primary research interests are lifestyle disorders and cost effective interventions in resource-poor rural areas. Dr. Tiwari's other interests are the examination of the links between health and human behavior, the role of health in socio-economic development and challanges of accessibility and affordability in healthcare delivery. Dr. Tiwari is working closely with various national and international agencies actively involved in addressing the challanges facing basic healthcare services for the poor and increasing burden of lifestyle diseases in developing countries like India.

Robert Tjian, PhD
Robert Tjian is Professor of Biochemistry and Molecular Biology, Faculty Director of the Health Sciences Initiative and Director of the Stem Cell Center at the University of California, Berkeley, and a Howard Hughes Investigator. Foremost among his achievements, Dr. Tjian is known for helping to shed light on the molecular machinery used by human cells to decode the genome and control the switches that turn genes on and off. His research has provided insights into Huntington's disease, cancer, diabetes, and infertility, and he has received many awards for his work, including California Scientist of the Year in 1994 and the National Academy of Sciences Monsanto Award for Molecular Biology. Dr. Tjian is co-founder of Tularik, Inc., a San Francisco biotech company that is a leader in regulating gene expression by targeting transcription factors and other proteins involved in DNA transactions. He also chairs the UC Berkeley Chancellor's Advisory Council on Biology.

Jennifer Vasterling, PhD
Jennifer J. Vasterling serves as the Chief of Psychology at the VA Boston Healthcare System and as a clinical investigator within the Behavioral Sciences Division of the National Center for PTSD. Dr. Vasterling also is a Clinical Professor of Psychiatry and Neurology at Tulane University School of Medicine. She obtained her PhD in clinical psychology from Vanderbilt University in 1988. Trained as a clinical neuropsychologist, Dr. Vasterling’s research has centered on furthering understanding of the cognitive and emotional changes that accompany war-zone deployment and post-traumatic stress disorder. Her recent work includes a longitudinal study examining neuropsychological and emotional outcomes of the Iraq War. This effort is unique in that it tracks the mental health of deploying soldiers, starting when they are deployed and following them after they return from Iraq.

Gregory Verdine, PhD
Gregory L. Verdine is Harvard College Professor and Erving Professor of Chemistry at Harvard University. In recent years, Dr. Verdine has established himself as one of the pioneers of the emerging discipline known as chemical biology, which seeks to understand the functions of small molecules, their interplay in the cell, and their effect on biological processes. He has studied the processes underlying control of gene expression and preservation of genomic integrity, and his work has shed light on the biochemical and structural basis for enzymatic recognition and repair of mutagenic damage in DNA. He joined the faculty of Harvard’s Department of Chemistry in 1988 and quickly rose among the ranks, eventually becoming the Erving Professor of Chemistry in 2002. Dr. Verdine has received numerous awards and honors, including the National Science Foundation Presidential Young Investigator Award, the Sloan Fellowship, Searle Scholar Award, and an Eli Lilly Award in Biological Chemistry.

Nora Volkow, MD
Nora D. Volkow is Director of the National Institute on Drug Abuse (NIDA), a post she has held since 2003. A leading authority on drug addiction research and brain imaging, Dr. Volkow came to NIDA from Brookhaven National Laboratory, where she held several positions, including Associate Director for Life Sciences, Director of Nuclear Medicine, and Director of the NIDA-Department of Energy Regional Neuroimaging Center. Additionally, she was a professor in the Department of Psychiatry and Associate Dean of the medical school at the State University of New York-Stony Brook. Her research has focused on the brain's dopamine system and has documented how changes to it affect motivation, drive and pleasure, as well as the decline of brain dopamine function with age. Among her accolades, Dr. Volkow was named "Innovator of the Year" in 2000 by U.S. News and World Report. She obtained her MD from the National University of Mexico.

Kenneth Weakley, MBA
Kenneth Weakley is a Managing Director of Credit Suisse in the Equity Research Department within the Investment Banking Division, responsible for covering health care facilities companies. Prior to joining Credit Suisse in July 2007, Mr. Weakley worked at UBS Investment Research. He has been covering health care facilities companies for more than 12 years, and has been recognized by Institutional Investor and Greenwich Associates as a leading health care facilities analyst. He holds a bachelor’s in economics and a bachelor’s in business from Rhode Island College, and an MBA from the State University of New York – Buffalo.

Daniel Weinberger, MD
Daniel Weinberger is a senior investigator at the Clinical Brain Disorders Branch of the National Institute of Mental Health, a division of the National Institutes of Health. Dr. Weinberger’s research focuses on basic neurobiological and genetic mechanisms of neuropsychiatric disorders, especially schizophrenia. His team of about 60 scientists and graduate students has pinpointed six genes associated with brain disorders since the data resources of the Human Genome Project began coming online in the mid 1990s. Along with that work, he has spent a decade helping to organize and direct interdisciplinary teams that explored state-of-the-art brain-imaging systems designed to pinpoint chemical reactions in mentally ill patients. Dr. Weinberger is the recipient of the Research Prize of the World Federation of Societies of Biological Psychiatry, the Foundations’ Fund Prize from the American Psychiatric Association, and the Lieber Prize from NARSAD, formerly known as National Alliance for Research on Schizophrenia and Depression.

Irving Weissman, MD
Irving L. Weissman is Karel and Avice Beekhuis Professor of Cancer Biology at Stanford University, where he also serves as Director of both the Comprehensive Cancer Center and Institute for Stem Cell Biology and Regenerative Medicine. Dr. Weissman was the first to isolate an adult stem cell in 1988 when he isolated a blood-forming stem cell in mice. He later isolated the blood-forming stem cell in humans, the human neuronal stem cell, and more recently the leukemia stem cell in a type of human myeloid leukemia. His recent focus has been the purification, biology, transplantation and evolution of stem cells. He was a founding member of the Amgen, DNAX, and T-Cell Sciences scientific advisory boards and has received the Kovalenko Medal of the National Academy of Sciences, the De Villiers Award of the Leukemia Society of America and the 2002 California Scientist of the Year from the California Science Center.

Jonathan Weissman, PhD
Jonathan Weissman is a Professor of Cellular and Molecular Pharmacology, and of Biochemistry and Biophysics at the University of California San Francisco, and an Investigator for the Howard Hughes Medical Institute, Bethesda, Maryland. His research lab is looking at how cells ensure that proteins fold into their correct shape, as well as the role of protein misfolding in disease and normal physiology. The importance of proper protein folding is underscored by the fact that a number of diseases, including Alzheimer's and those involving infectious proteins (prions), result from protein-misfolding events. He is also developing experimental and analytical approaches for exploring the organizational principles of complex biological systems. Dr. Weissman is on the executive committee of the Institute for Neurodegenerative Diseases, and has published more than 160 research articles. He received his PhD in Physics from MIT.

Terrie Fox Wetle, PhD
Terrie Fox Wetle is Associate Dean of Medicine for Public Health and Professor of Community Health at Brown Medical School. She served as Deputy Director of the National Institute on Aging at NIH. Dr. Wetle is currently President of the American Federation for Aging Research and a past president of the Gerontological Society of America. She has consulted on the development of geriatric services in several Asian countries including the People's Republic of China, Taiwan, Hong Kong, Singapore, Indonesia, and Thailand, and recently was a visiting professor at the C.N.R. Instituto di Neuroscienze, University of Padova, Italy. Her research interests include social gerontology, end of life care, and ethical issues in geriatric care. Her most recent co-edited books are Financing Long Term Care: The Integration of Public and Private Roles and Improving Aging and Public Health Research: Qualitative and Mixed Methods.

R. Sanders Williams, MD
R. Sanders Williams is Dean of the Duke University School of Medicine and Senior Vice Chancellor for Academic Affairs at Duke University Medical Center. Under his leadership during the past six years, the school of medicine has experienced significant growth, including a near doubling of NIH research funding to almost $350 million, the construction of five new research buildings, the development of several new national and international research institutes, an increase of several hundred faculty, and the creation of the Duke/National University of Singapore Graduate Medical School, which he has personally overseen. Dr. Williams is a practicing cardiologist and basic science researcher. Prior to his appointment at Duke, he held leadership positions at the University of Texas Southwestern Medical Center. Dr. Williams has published more than 150 journal articles and holds five patents. At the national level, he has advocated more effective use of cardiac-based, personalized medicine as a step to enhance health outcomes and control costs.

Ron Winslow
Ron Winslow is Deputy Editor of Health and Science and a senior medical and health care writer for The Wall Street Journal. In the past 16 years, he has written about 1,100 articles describing new medical and health care research and chronicling the economic forces transforming the nation’s health care system. He received the Howard Lewis Award for career achievement from the American Heart Association in 2003 and his work has been honored by the National Alliance for the Mentally Ill and other groups. He is a member of the National Association of Science Writers, and was a founding board member of the Association of Health Care Journalists.

Nathan Wolfe, PhD
Nathan Wolfe is Professor of Epidemiology at the UCLA School of Public Health. Dr. Wolfe’s research combines methods from ecology, anthropology, evolutionary biology and molecular virology to study the biology of viral emergence. In particular, he seeks to identify the factors that allow viruses to cross from animals into humans and to develop systems to monitor viruses before they become epidemics. Prior to joining UCLA in 2006, he served for three years as an assistant professor in the Department of Epidemiology at the Johns Hopkins University Bloomberg School of Public Health. In 2005, he was awarded the NIH Director's Pioneer Award to establish a surveillance system involving subsistence hunters in regions of high biodiversity to monitor for the transmission of new viruses, such as Ebola and SARS, from animals to humans. The recipient of a Fulbright fellowship, Dr. Wolfe received his PhD in Immunology and Infectious Diseases from Harvard University.

Malissa Wood, MD, FACC
Malissa J. Wood is a clinical cardiologist and staff physician in the Cardiac Ultrasound Laboratory at Massachusetts General Hospital in Boston, where she also serves as the Co-Director of the MGH Heart Center Women’s Health Program.  Dr. Wood’s clinical practice is primarily devoted to the diagnosis and treatment of heart disease in women and athletes, and her research interests involve using echocardiography to better understand cardiac adaptations to changing loading conditions.  Dr. Wood has published extensively in the area of cardiac adaptations to exercise training in athletes and is the principle investigator of several studies examining the use of new echocardiographic techniques.  Dr. Wood received her medical degree from the University of Missouri-Kansas City, and went on to complete her Internal Medicine and Cardiology training at Beth Israel Deaconess Medical Center in Boston where she served as Chief Medical Resident.

Mary Woolley
Since 1990, Mary Woolley has been president and CEO of Research!America, the nation’s largest not-for-profit alliance working to make research to improve health a higher national priority. Its 500+ organizational members represent the voices of 125 million Americans. Under her leadership, Research!America's membership has more than quadrupled as it has earned the attention and respect of research, media and community leaders with its signature public opinion polls and advocacy resource materials. She is an elected member of the National Academy of Sciences’ Institute of Medicine and fellow of the American Association for the Advancement of Science. She serves on the Harvard School of Public Health Board of Overseers and the IBM Life Sciences Council, among other volunteer activities. She has a 25-year editorial and publication history on science advocacy, policy and public opinion. She was educated at San Francisco State University and Stanford University and is a native of Chicago.

Steven Zeisel, MD, PhD
Steven Zeisel is a Kenan Distinguished University Professor in the Departments of Nutrition and Pediatrics at the University of North Carolina at Chapel Hill. He was recently named Director of the university’s Nutrition Research Institute at the newly formed North Carolina Research Campus in Kannapolis. Dr. Zeisel’s research focuses on nutrient metabolism, with special emphasis on establishing human nutrient requirements and on identifying cancer-causing agents produced within our bodies. In 2002-2003, Dr. Zeisel was President of the nation's most prestigious academic nutrition society, The American Society for Nutrition Sciences. Additionally, he was Editor-in-chief of the Journal of Nutritional Biochemistry from 1989 to 2000. Dr. Zeisel is a leader in the development of an innovative computer-based nutrition curriculum used by more than 150 medical schools, funded in part by the National Cancer Institute. He earned his MD from Harvard, was a pediatric resident at Yale, and received his PhD from MIT.

Paul Zimmet, AO, MD, PhD
Paul Zimmet is Director of the International Diabetes Institute and Hon. Professor at Monash University in Australia. He co-chairs the International Diabetes Federation Task Force on Epidemiology and Prevention. He designed and leads the team carrying out the “AusDiab Study,” the first national diabetes and obesity study in Australia. He is widely recognized for his studies in Indian and Pacific Ocean populations which have provided new insights into the genetic and environmental contribution to type 2 diabetes and obesity as well as the role of socio-cultural change. He has received numerous international awards for his research, including the 2007 International Novartis Award for accomplishments in research that have had a major impact in diabetes. He received the national award of Officer of the Order of Australia for distinguished services to medicine, nutrition and the biotechnology industry. He chairs the scientific advisory boards for Chemgenex Pharmaceuticals and the Institute of Diabetes Discovery.

Douglas Zipes, MD
Douglas P. Zipes is a Distinguished Professor Emeritus at the Indiana University School of Medicine and a past president of both the American College of Cardiology and the Heart Rhythm Society. Dr. Zipes specializes in the research and treatment of cardiac arrhythmias and was a member of the team that developed the first cardioverter, a device that administers electric shock to restore the heart’s normal rhythm. He also pioneered an alcohol ablation catheterization technique, which cures some arrhythmias, and is a specialist on Wolf-Parkinson-White Syndrome, Marfan Syndrome, and sudden death in athletes. Dr. Zipes has received many awards in recognition of his work, including the Distinguished Achievement Award from the American Heart Association. He was founding editor of the Journal of Cardiovascular Electrophysiology and the new journal of the Heart Rhythm Society. He received his MD from Harvard Medical School and his postgraduate training at Duke University Medical Center.

John Zogby
John Zogby is President and Chief Executive Officer of Zogby International, a leading public opinion and market research firm. Mr. Zogby routinely conducts polls on health care reform and global health efforts. Among his accomplishments, he is widely recognized for correctly predicting the cliffhanger result of the 2000 presidential election for George W. Bush, in contrast to most other pollsters who had projected that Bush would win easily. Mr. Zogby established his firm in 1984 and since then has been tracking public opinion in North America, Latin America, the Middle East, Asia and Europe. He has written guest editorials for The New York Times and The Wall Street Journal, among other major newspapers, and he is the author of a forthcoming portrait of the new American consumer, which will be published by Random House this fall. Mr. Zogby holds degrees in history from Le Moyne College and Syracuse University.